Prevention and treatment of venous thromboembolism in patients with IBD: A trail still climbing

Alfredo Papa, Valerio Papa, Manuela Marzo, Franco Scaldaferri, Luigi Sofo, Gian L. Rapaccini, Silvio Danese, Antonio Gasbarrini

Research output: Contribution to journalArticle

Abstract

Venous thromboembolism (VTE) represents one of the most common and life-threatening extraintestinal complications of inflammatory bowel disease (IBD). Therefore, the prevention of VTE is essential and foremost involves the assessment of individual patient risk factors for VTE and, consequently, the correction of those risk factors that are modifiable. Mechanical and pharmacological prophylaxis are highly effective at preventing VTE in patients hospitalized for acute disease, and they are recommended by the leading guidelines for hospitalized patients with IBD. Unfortunately, several recent surveys reported that prophylaxis against VTE is still poorly implemented because of concerns about its safety and a lack of awareness of the magnitude of thrombotic risk in patients with IBD. Therefore, further efforts are required to increase the thromboprophylaxis rate in these patients to bridge the gap between the best care and standard care and, consequently, to avoid preventable VTE-associated morbidity and mortality. This review provides insight on the critical points that persist on the prevention and treatment of VTE in patients with IBD.

Original languageEnglish
Pages (from-to)1204-1213
Number of pages10
JournalInflammatory Bowel Diseases
Volume21
Issue number5
DOIs
Publication statusPublished - Mar 3 2015

Fingerprint

Venous Thromboembolism
Inflammatory Bowel Diseases
Therapeutics
Acute Disease
Standard of Care
Pharmacology
Guidelines
Morbidity
Safety
Mortality

Keywords

  • anticoagulants
  • inflammatory bowel disease
  • low-molecular-weight heparin
  • thromboprophylaxis
  • unfractionated heparin
  • venous thromboembolism

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Papa, A., Papa, V., Marzo, M., Scaldaferri, F., Sofo, L., Rapaccini, G. L., ... Gasbarrini, A. (2015). Prevention and treatment of venous thromboembolism in patients with IBD: A trail still climbing. Inflammatory Bowel Diseases, 21(5), 1204-1213. https://doi.org/10.1097/MIB.0000000000000310

Prevention and treatment of venous thromboembolism in patients with IBD : A trail still climbing. / Papa, Alfredo; Papa, Valerio; Marzo, Manuela; Scaldaferri, Franco; Sofo, Luigi; Rapaccini, Gian L.; Danese, Silvio; Gasbarrini, Antonio.

In: Inflammatory Bowel Diseases, Vol. 21, No. 5, 03.03.2015, p. 1204-1213.

Research output: Contribution to journalArticle

Papa, A, Papa, V, Marzo, M, Scaldaferri, F, Sofo, L, Rapaccini, GL, Danese, S & Gasbarrini, A 2015, 'Prevention and treatment of venous thromboembolism in patients with IBD: A trail still climbing', Inflammatory Bowel Diseases, vol. 21, no. 5, pp. 1204-1213. https://doi.org/10.1097/MIB.0000000000000310
Papa, Alfredo ; Papa, Valerio ; Marzo, Manuela ; Scaldaferri, Franco ; Sofo, Luigi ; Rapaccini, Gian L. ; Danese, Silvio ; Gasbarrini, Antonio. / Prevention and treatment of venous thromboembolism in patients with IBD : A trail still climbing. In: Inflammatory Bowel Diseases. 2015 ; Vol. 21, No. 5. pp. 1204-1213.
@article{859f858a677544d6839b0efd2b9b626d,
title = "Prevention and treatment of venous thromboembolism in patients with IBD: A trail still climbing",
abstract = "Venous thromboembolism (VTE) represents one of the most common and life-threatening extraintestinal complications of inflammatory bowel disease (IBD). Therefore, the prevention of VTE is essential and foremost involves the assessment of individual patient risk factors for VTE and, consequently, the correction of those risk factors that are modifiable. Mechanical and pharmacological prophylaxis are highly effective at preventing VTE in patients hospitalized for acute disease, and they are recommended by the leading guidelines for hospitalized patients with IBD. Unfortunately, several recent surveys reported that prophylaxis against VTE is still poorly implemented because of concerns about its safety and a lack of awareness of the magnitude of thrombotic risk in patients with IBD. Therefore, further efforts are required to increase the thromboprophylaxis rate in these patients to bridge the gap between the best care and standard care and, consequently, to avoid preventable VTE-associated morbidity and mortality. This review provides insight on the critical points that persist on the prevention and treatment of VTE in patients with IBD.",
keywords = "anticoagulants, inflammatory bowel disease, low-molecular-weight heparin, thromboprophylaxis, unfractionated heparin, venous thromboembolism",
author = "Alfredo Papa and Valerio Papa and Manuela Marzo and Franco Scaldaferri and Luigi Sofo and Rapaccini, {Gian L.} and Silvio Danese and Antonio Gasbarrini",
year = "2015",
month = "3",
day = "3",
doi = "10.1097/MIB.0000000000000310",
language = "English",
volume = "21",
pages = "1204--1213",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Prevention and treatment of venous thromboembolism in patients with IBD

T2 - A trail still climbing

AU - Papa, Alfredo

AU - Papa, Valerio

AU - Marzo, Manuela

AU - Scaldaferri, Franco

AU - Sofo, Luigi

AU - Rapaccini, Gian L.

AU - Danese, Silvio

AU - Gasbarrini, Antonio

PY - 2015/3/3

Y1 - 2015/3/3

N2 - Venous thromboembolism (VTE) represents one of the most common and life-threatening extraintestinal complications of inflammatory bowel disease (IBD). Therefore, the prevention of VTE is essential and foremost involves the assessment of individual patient risk factors for VTE and, consequently, the correction of those risk factors that are modifiable. Mechanical and pharmacological prophylaxis are highly effective at preventing VTE in patients hospitalized for acute disease, and they are recommended by the leading guidelines for hospitalized patients with IBD. Unfortunately, several recent surveys reported that prophylaxis against VTE is still poorly implemented because of concerns about its safety and a lack of awareness of the magnitude of thrombotic risk in patients with IBD. Therefore, further efforts are required to increase the thromboprophylaxis rate in these patients to bridge the gap between the best care and standard care and, consequently, to avoid preventable VTE-associated morbidity and mortality. This review provides insight on the critical points that persist on the prevention and treatment of VTE in patients with IBD.

AB - Venous thromboembolism (VTE) represents one of the most common and life-threatening extraintestinal complications of inflammatory bowel disease (IBD). Therefore, the prevention of VTE is essential and foremost involves the assessment of individual patient risk factors for VTE and, consequently, the correction of those risk factors that are modifiable. Mechanical and pharmacological prophylaxis are highly effective at preventing VTE in patients hospitalized for acute disease, and they are recommended by the leading guidelines for hospitalized patients with IBD. Unfortunately, several recent surveys reported that prophylaxis against VTE is still poorly implemented because of concerns about its safety and a lack of awareness of the magnitude of thrombotic risk in patients with IBD. Therefore, further efforts are required to increase the thromboprophylaxis rate in these patients to bridge the gap between the best care and standard care and, consequently, to avoid preventable VTE-associated morbidity and mortality. This review provides insight on the critical points that persist on the prevention and treatment of VTE in patients with IBD.

KW - anticoagulants

KW - inflammatory bowel disease

KW - low-molecular-weight heparin

KW - thromboprophylaxis

KW - unfractionated heparin

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84924936836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924936836&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000000310

DO - 10.1097/MIB.0000000000000310

M3 - Article

C2 - 25581834

AN - SCOPUS:84924936836

VL - 21

SP - 1204

EP - 1213

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 5

ER -